Roche & Generic Firms Propose SMART-er Accutane Risk Management Program
This article was originally published in The Pink Sheet Daily
"Consensus proposal" includes mandatory registration of female patients and prescribers. The proposed enhancements to SMART incorporate aspects of Celgene's STEPS program for Thalomid, but avoid restricted distribution.
You may also be interested in...
Four patents relating to the STEPS risk management program for Thalomid are an “obstacle” to implementing an augmented isotretinoin program, FDA says. The agency’s Office of Chief Counsel is reviewing the issue.
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.